![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00011076 |
This study will examine the effectiveness of the drug pirfenidone (Deskar) in improving heart function in patients with hypertrophic cardiomyopathy (HCM). Stiffening of the heart muscle in patients with HCM impairs the heart's ability to relax and thus fill and empty properly. This can lead to heart failure, breathlessness and excessive fatigue. The heart's inability to relax may be due to scarring, or fibrosis, in the muscle wall. This study will test whether pirfenidone can reduce fibrosis, improve heart relaxation and reduce abnormal heart rhythms.
Men and women 20 to 75 years old with HCM may be eligible for this study. Participants will undergo a physical examination, blood tests, and other tests and procedures, described below, to assess heart function. When the tests are completed, patients will be randomly assigned to one of two treatment groups. One group will take a pirfenidone capsule and the other will take a placebo (a look-alike pill with no active ingredient) twice a day with meals for 6 months. For the pirfenidone group, the dose of drug will be increased gradually from 400 to 800 milligrams. At the end of 6 months, all patients will repeat the physical examination and heart tests that were done before starting medication. These include:
Condition | Intervention | Phase |
---|---|---|
Hypertrophic Cardiomyopathy |
Drug: Pirfenidone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Safety/Efficacy Study |
Official Title: | Double-Blind Placebo-Controlled Study of Pirfenidone, A Novel Anti-Fibrotic Drug in Symptomatic Patients With Hypertrophic Cardiomyopathy (HCM) Associated With Left Ventricular Diastolic Function |
Estimated Enrollment: | 50 |
Study Start Date: | February 2001 |
Estimated Study Completion Date: | April 2003 |
Left ventricular (LV) diastolic dysfunction and arrhythmias are important causes of morbidity and mortality in HCM. These abnormalities are believed to be in part due to myocardial fibrosis which frequently complicates HCM. Several studies indicate that pirfenidine can safely inhibit progression or cause regression of fibrotic lesions. We therefore propose to perform a six-month study that examines the ability of pirfenidone to improve LV diastolic dysfunction, exercise performance, and electrophysiologic abnormalities in symptomatic patients with severe HCM.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
Male or female patient aged 20 to 75 years.
Cardiac symptoms: New York Heart Association Functional Class II-IV despite medical therapy.
Maximum LV wall thickness greater than 15 mm assessed by echo or MRI.
Mean pulmonary capillary wedge pressure of greater than or equal to 18 mm Hg and/or LV end-diastolic pressure of greater than or equal to 18 mm Hg.
EXCLUSION CRITERIA:
LV outflow tract gradient greater than 40 mm Hg by cardiac catheterization.
Coronary artery disease (greater than 50% arterial luminal narrowing of a major epicardial vessel).
Chronic atrial flutter/fibrillation
Pregnancy and breast-feeding.
Treatment with immunosuppressant medication in last 90 days.
Active neoplastic disease.
Significant renal (serum creatinine greater than 1.5 x upper reference limit) or hepatic (transaminases greater than 2 x upper reference limit) dysfunction.
Use of over-the-counter medications, or herbal therapies that may be cardioactive.
Study ID Numbers: | 010066, 01-H-0066 |
Study First Received: | February 9, 2001 |
Last Updated: | March 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00011076 |
Health Authority: | United States: Federal Government |
Deskar Fibrosis Myocardium Scarring Arrhythmia |
Hypertrophic Cardiomyopathy Left Ventricular Diastolic Dysfunction Myocardial Fibrosis Arrhythmia |
Pathological Conditions, Anatomical Heart Diseases Fibrosis Constriction, Pathologic Aortic valve stenosis Cardiomyopathies Heart Valve Diseases |
Pirfenidone Hypertrophy Cardiomyopathy, Hypertrophic Aortic Valve Stenosis Arrhythmias, Cardiac Cicatrix |
Anti-Inflammatory Agents Antineoplastic Agents Physiological Effects of Drugs Pharmacologic Actions Aortic Stenosis, Subvalvular Sensory System Agents Analgesics, Non-Narcotic |
Therapeutic Uses Cardiovascular Diseases Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |